Skip to main content
    F

    Foghorn Therapeutics Inc (FHTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.79
    -0.28 (-13.53%)

    Market Cap: $124.12M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Foghorn Therapeutics Inc (FHTX) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Foghorn Therapeutics (FHTX) trades at 40.1x trailing earnings and 1.1x sales. Its P/S of 1.1x is below its 5-year median of 11.9x.

    Current Multiples

    Its enterprise value is 19.9x its EBITDA.

    MultipleValue
    P/E (trailing)40.1x
    Forward P/EN/A
    Price to sales1.1x
    EV/EBITDA19.9x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S1.1x11.9xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 6 year ends shown, its P/S ranged from 7.9x in 2023 to 640.0x in 2021.

    Year endPriceP/SP/B
    2025$5.4011.0xN/A
    2024$4.7211.2xN/A
    2023$6.457.9xN/A
    2022$6.3813.8xN/A
    2021$22.87640.0x8.7x
    2020$20.27469.1x2.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About FHTX

    What is FHTX's price to sales ratio?

    Foghorn Therapeutics has a price to sales ratio of 1.1x.